skyrizi and tirzepatide is projected to have over $70 billion in annual sales by 2032. That makes it the best-selling drug in history. --- According to Evaluate Ltd, Eli Lilly will lead the global Comparative ocular outcomes of tirzepatide

201 Uric acid-lowering therapy effectively reduces both systolic and diastolic blood pressure in pediatric and adolescent patients newly diagnosed with essential hypertension, particularly in young individuals with a short duration of hypertension and preserved renal function

I think that theres a tremendous future interest in combining these kinds of drugs

Compounded medications are not FDA-approved as finished products and may differ in formulation and concentration from FDA-approved brand-name drugs

This dual approach can offer certain patients a greater chance at significant weight loss as compared to single-hormone medications, like Ozempic